A study to assess COPD Symptom-based Management and to Optimise treatment Strategy in Japan (COSMOS-J) based on GOLD 2011
Received 15 May 2013
Accepted for publication 28 June 2013
Published 3 October 2013 Volume 2013:8 Pages 453—459
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Tomoko Betsuyaku,1 Motokazu Kato,2 Keisaku Fujimoto,3 Gerry Hagan,4 Akihiro Kobayashi,5 Hideki Hitosugi,5 Mark James,5 Paul W Jones6
1Division of Pulmonary Medicine, Department of Medicine, Keio University, Tokyo, Japan; 2Department of Respiratory Disease, Kishiwada City Hospital, Osaka, Japan; 3Department of Clinical Laboratory Sciences, Shinshu University, Nagano, Japan; 4Private Practice, Marbella, Spain; 5GlaxoSmithKline KK, Tokyo, Japan; 6Division of Clinical Science, St George’s, University of London, London, UK
Background and objective: The Global initiative for chronic Obstructive Lung Disease (GOLD) Committee has proposed a COPD assessment framework focused on symptoms and on exacerbation risk. This study will evaluate a symptom and exacerbation risk-based treatment strategy based on GOLD in a real-world setting in Japan. Optimal management of COPD will be determined by assessing symptoms using the COPD Assessment Test (CAT) and by assessing the frequency of exacerbations.
Methods: This study (ClinicalTrials.gov identifier: NCT01762800) is a 24-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. It aims to recruit 400 patients with moderate-to-severe COPD. Patients will be randomized to receive treatment with either salmeterol/fluticasone propionate (SFC) 50/250 µg twice daily or with tiotropium bromide 18 µg once daily. Optimal management of patients will be assessed at four-weekly intervals and, if patients remain symptomatic, as measured using the CAT, or experience an exacerbation, they have the option to step up to treatment with both drugs, ie, SFC twice daily and tiotropium once daily (TRIPLE therapy). The primary endpoint of the study will be the proportion of patients who are able to remain on the randomized therapy.
Results: No data are available. This paper summarizes the methodology of the study in advance of the study starting.
Conclusion: The results of this study will help physicians to understand whether TRIPLE therapy is more effective than either treatment strategy alone in controlling symptoms and exacerbations in patients with moderate-to-severe COPD. It will also help physicians to understand the GOLD recommendation work in Japan.
Keywords: COPD, GOLD, symptom, exacerbation risk, TRIPLE therapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]